- Home
- BNS vs SNY Comparison
BNS vs SNY Comparison
Compare BNS & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNS | SNY |
|---|---|---|
| Founded | 1832 | 1994 |
| Country | Canada | France |
| Employees | N/A | 74846 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.1B | 104.5B |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | BNS | SNY |
|---|---|---|
| Price | $86.08 | $42.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $106.00 | $58.00 |
| AVG Volume (30 Days) | 2.2M | ★ 3.5M |
| Earning Date | 05-27-2026 | 04-23-2026 |
| Dividend Yield | ★ 4.21% | 3.47% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.54 | $3.49 |
| Revenue Next Year | $4.77 | $6.10 |
| P/E Ratio | $18.76 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.29 | $40.89 |
| 52 Week High | $87.98 | $52.68 |
Technical Indicators
Market Signals| Indicator | BNS | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 66.76 | 44.93 |
| Support Level | $74.37 | $42.30 |
| Resistance Level | N/A | $48.76 |
| Average True Range (ATR) | 1.21 | 0.73 |
| MACD | 0.07 | -0.14 |
| Stochastic Oscillator | 73.52 | 41.29 |
Price Performance
Historical ComparisonAbout BNS Bank Nova Scotia Halifax Pfd 3
The Bank of Nova Scotia is a global financial services provider with over CAD 1.46 trillion in assets as of the end of fiscal 2025. The bank has four major business segments: Canadian banking, international banking, global wealth management, and global banking and markets. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in the Latin America region.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.